Antibodies Journal
Explore evitria’s Antibody Journal for in-depth articles on antibody engineering, CHO cell expression systems, and advancements in recombinant antibody production services.
Articles about Antibodies Journal (2)
-
What is the difference between a monoclonal and a bispecific antibody?
Both monoclonal and bispecific antibodies come with numerous benefits, but have several differences that set them apart. We will review them in this article.
-
Speed vs. Quality in Early Drug Development: Striking the Right Balance for Antibody Therapeutics
In drug development, speed without reproducibility risks costly setbacks. This article shows how high-quality antibody materials, early testing, and smart design enable faster, more reliable programs without compromising rigor.
-
Why Promising Antibody Candidates Fail Before Clinical Trials – and How to Avoid It
Despite strong market growth, most antibody candidates fail early due to developability, pharmacokinetics, or immunogenicity issues. This article outlines key risks and strategies to de-risk development and speed the path from discovery to IND.
-
Fast-Tracking Bispecific Antibody Development: What Can Go Wrong?
Bispecific antibodies hold great promise, but rushing development can trigger design and manufacturing risks. This article explores how smart strategies and expert partnerships accelerate bsAb programs without compromising quality.
-
The Risks of Over-Promising in Early-Stage Biologics Development
In early biologics development, over-promising can derail programs and erode trust. This article explores the causes, consequences, and how data-driven planning safeguards progress and credibility.
-
The Stability Problem: Why Some Recombinant Antibodies Don’t Make It to Market
Stability is key to antibody success, but physical, chemical, and biological issues often derail candidates. This article covers causes, consequences, and strategies to improve stability, manufacturability, and speed development to market.
-
Afucosylated recombinant antibodies
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.
-
Bengt Thorsson and Johan Rockberg to join Atlas Antibodies’ Board of Directors
We are pleased to announce the election of Bengt Thorsson and Johan Rockberg to Atlas Antibodies’ Board of Directors, following the AGM on May 23, 2025. Åsa Riisberg has been re-elected as Chair of the Board and Catarina Flyborg, Gavin Wood, Christian Eberle and Louise Kores have been re-elected as board members. We thank Mathias Uhlén and Lotta Ljungqvist for their years of dedicated service and valuable contributions as they step down from the Board. The size of the Board remains unchanged. May 2025 “It’s a great pleasure to welcome Bengt Thorsson and Johan Rockberg to the Board of Directors of…
-
Press release: evitria Celebrates 15 Years with Exclusive Giveaway for Industry Experts
Tickets for Festival of Biologics, Networking Dinner, and Exclusive Tour of evitria AG in Zürich Up for Grabs Zurich, Switzerland – March 2025 – evitria, a leading provider of antibody development services, is celebrating its 15th anniversary with an exciting giveaway that offers an exclusive opportunity to attend the Festival of Biologics in Basel, Switzerland. The company is rewarding three industry professionals per month with tickets to the prestigious event, a Swiss-style networking dinner, and a behind-the-scenes tour of evitria’s world-class facility in Zürich. “We are incredibly proud of the impact we’ve made over the past 15 years in advancing…
-
Engineering bispecific antibodies
Recorded Presentation: From mAb to bAb Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a case study for the transformation of a mAb into a bsAb. Request presentation record Speaker Desmond Schofield, pHD Learn more How to choose a bispecific antibody format Bispecific antibody production service bYlok® bispecific pairing technology in bsAb production
-
evitria and Lonza Sign License Agreement to Provide Fast Access to bYlok® Bispecific Antibodies for Discovery-Stage Transient Expression Research
Zurich-based evitria AG has entered a non-exclusive license agreement with Lonza for its bYlok® technology, enabling simple and reliable development of IgG-like bispecific antibodies.
-
Transient transfection vs. stable transfection
Both transient and stable transfection are essential methods in genetic engineering. But what are the differences between them? Let’s find out in this article.
